Sanofi Consumer Healthcare India Limited has announced its financial results for the third quarter, showcasing robust growth across key business segments. The company's performance reflects a strong recovery and expansion in both domestic and export markets.

Financial Highlights

For the quarter ended September 30, Sanofi Consumer Healthcare India reported:

The company's revenue from operations saw a significant increase of 46% year-on-year, reaching ₹2,339.00 million. This growth was driven by a 20% increase in domestic sales and a substantial rise in export sales, which grew by over 1000% from a low base.

Nine-Month Performance

For the nine-month period ended September 30:

The company's revenue for the nine-month period grew by 13% to ₹6,274.00 million, while profit after tax increased by 27% to ₹1,736.00 million.

Key Developments

Sanofi Consumer Healthcare India has successfully relaunched all previously recalled products:

• Depura Adult and Combiflam Suspension were reintroduced earlier in the year
• Allegra Suspension and Depura Kids were relaunched in the September quarter

These relaunch efforts have helped the company re-establish its market presence within the year, contributing to the strong performance in the domestic market.

Management Commentary

Himanshu Bakshi, Managing Director of Sanofi Consumer Healthcare India Limited, commented on the results: "Our third-quarter results reflect the strength of our diversified portfolio driving sustained growth momentum this quarter. The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year. Anchored in science and guided by purpose, we remain committed to making self-care simpler, more accessible and more effective for every consumer."

Business Segment and Product Portfolio

Sanofi Consumer Healthcare India operates in the pharmaceutical business segment, with key brands including Allegra, DePURA, Avil, and Combiflam. The company's portfolio encompasses products in Allergy, Digestive Wellness, Pain Care, and Multivitamins categories.

Corporate Updates

On April 30, Sanofi globally closed the sale of a 50% controlling stake of Opal JVco S.a.r.l (Opella group) to Clayton, Dubilier & Rice Fund XII, L.P. Sanofi retains a significant 48.2% stake, while Bpifrance owns a 1.8% stake. As a result, the ultimate parent of Sanofi Consumer Healthcare India is now Opal JVco S.a.r.l instead of Sanofi.

Conclusion

Sanofi Consumer Healthcare India's Q3 results demonstrate the company's resilience and growth potential in the consumer healthcare sector. The successful relaunch of key products, coupled with strong performance in both domestic and export markets, positions the company well for continued growth in the coming quarters.

Investors and stakeholders should note that the quarter and nine-month results are not directly comparable to the previous year due to the demerger and voluntary recall of certain key brand variants in the domestic market. However, the current results indicate a positive trajectory for the company's operations and financial performance.

Sanofi Consumer Healthcare India Limited, a prominent player in the consumer healthcare sector, has announced a significant change in its leadership team. The company has appointed Richard D'souza as its new Chief Financial Officer (CFO), effective October 16, 2025. This strategic move, approved by the Board of Directors, aims to strengthen the company's financial leadership and drive future growth.

Appointment Details

The appointment of Richard D'souza comes after careful consideration by the company's Board of Directors, based on recommendations from the Nomination and Remuneration Committee and in consultation with the Audit Committee. This decision underscores Sanofi's commitment to maintaining strong financial governance and strategic financial management.

Richard D'souza: A Seasoned Financial Expert

Richard D'souza brings a wealth of experience to his new role at Sanofi Consumer Healthcare India. Here's a closer look at his impressive background:

Impact on Sanofi Consumer Healthcare India

The appointment of Richard D'souza as CFO is expected to bring several benefits to Sanofi Consumer Healthcare India:

1. Strategic Financial Leadership: With his extensive experience in financial strategy and M&A, D'souza is well-positioned to guide Sanofi's financial decisions and growth initiatives.

2. Enhanced Governance: His background in corporate governance and investor relations may strengthen Sanofi's financial transparency and stakeholder communications.

3. Digital Transformation: D'souza's expertise in digital transformation could potentially drive technological advancements in Sanofi's financial operations.

4. Industry Insights: His experience in the FMCG and consumer goods sectors aligns well with Sanofi's consumer healthcare focus, potentially bringing valuable industry-specific insights.

The appointment of Richard D'souza as CFO marks an important step for Sanofi Consumer Healthcare India as it continues to strengthen its position in the competitive consumer healthcare market. Stakeholders will likely be watching closely to see how his expertise and leadership will contribute to the company's financial strategies and overall growth in the coming years.